A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia. The CATALYST Trial tested the rheumatoid arthritis treatment namilumab as a potential therapeutic to treat patients who are hospitalised with COVID-19 ... READ MORE
COVID-19 News
People with long COVID after hospitalisation face limited recovery after one year
People who were hospitalised with COVID-19 and continued to experience symptoms five months later show limited further recovery one year after hospital discharge, according to the latest results of a major national study looking at the long-term health impacts of COVID-19 on hospitalised ... READ MORE
COVID-19 infection more likely than vaccines to cause rare cardiovascular complications
Researchers have reported the results of the largest ever study to compare the risks of cardiovascular events - such as myocarditis, pericarditis, and cardiac arrhythmia - between different vaccines and COVID-19 infection, and the first to investigate the association between cardiac events and the ... READ MORE
RECOVERY Trial launched in South Africa
The world’s largest clinical trial investigating treatments for COVID-19 has now been launched in South Africa, with the first patient recruited today. Since March 2020, the RECOVERY Trial, which is supported by the NIHR Oxford BRC, has discovered three effective treatments for COVID-19: the ... READ MORE
Study uncovers gene that doubles risk of death from COVID-19
University of Oxford researchers have identified the gene responsible for doubling the risk of respiratory failure from COVID-19. Sixty percent of people with South Asian ancestry carry the high-risk genetic signal, which could partly explain the excess deaths seen in some UK communities, ... READ MORE
QCOVID study identifies vaccinated groups at highest risk hospitalisation and death
Researchers from the University of Oxford have identified which vaccinated people are at greatest risk from severe Covid-19 leading to hospitalisation or death, from 14 days after the second dose of vaccination, when substantial immunity should be expected. The research used the QCovid tool, ... READ MORE
RECOVERY Trial paper wins BMJ’s Research Paper of the Year Award
The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has been announced as the 2021 winner of The British Medical Journal’s prestigious UK Research Paper of the Year Award. The award recognises original UK research that has the potential to ... READ MORE
Moonshot initiative to develop affordable COVID-19 antivirals gets funding boost
The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from the Wellcome Trust, on ... READ MORE
MAIT Cell activation may play role in COVID-19 deaths, study finds
Oxford researchers have found a correlation between deaths from COVID-19 infections and a poorly coordinated systemic immune response, as well as increased activity by Mucosal Associated Invariant T cells, or ‘MAIT cells’. A study involving Oxford BRC-supported researchers published ... READ MORE
Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients
The COVID-19 pandemic has led to understandable anxiety within the blood cancer community about how their illness may affect their ability to overcome COVID-19 infection. Members of the Oxford Centre for Haematology have led a collaborative research project looking at the response of patients ... READ MORE
New study launched to understand vaccine escape
Oxford researchers will be involved in a major new study seeking to understand why some people become infected after vaccination or prior infection while others do not Oxford BRC-supported investigators already involved in the Protective Immunity from T-Cells in Healthcare workers (PITCH) study ... READ MORE
Vaccination still best protection, but less effective against Delta variant, study finds
The latest findings of an ongoing national study of COVID-19 immunity in households across the UK has found that the Pfizer-BioNTech and Oxford-AstraZeneca vaccines offer good protection against new infections of the Delta variant of concern, but that effectiveness is reduced compared with the Alpha ... READ MORE
Second study confirms benefits of budesonide in early stages of COVID-19
A UK-wide clinical study has confirmed the findings of an earlier Oxford BRC-supported study showing that the early treatment with the inhaled asthma medication budesonide speeds up recovery from COVID-19 and reduces the risk of hospitalisation and death. The latest study – part of the PRINCIPLE ... READ MORE
BRC-supported study receives Best Research Paper Award
A leading cardiology journal has named an academic paper written by Oxford BRC-supported researchers as its best research paper of 2020. The paper – which found that two common heart medication do not increase the risk of COVID-19 hospitalisation – was named by the BMJ Heart journal as the ... READ MORE
Liver problems common among COVID-19 patients, study finds
A study by Oxford University researchers has found that liver problems are common among patients with COVID-19. Patient data revealed that baseline hypoalbuminemia (an possible indication that the liver is producing low levels of albumin) and rising alkaline phosphatase (ALP), which can be a ... READ MORE
Oxford studies benefit from government funding of long COVID research
Thousands of people suffering with long COVID will benefit from new research programmes backed by £19.6 million to help better understand the condition, improve diagnosis and find new treatments. Among the 15 studies that will receive government funding through the National Institute for Health ... READ MORE
COVID-19 risk prediction tool wins national award
A COVID-19 risk prediction tool, developed with support from the NIHR Oxford Biomedical Research Centre (BRC) has won the Florence Nightingale Award for Excellence in Healthcare Data Analytics. The QCovid® COVID-19 Population Risk Assessment tool was developed by a cross-organisational team and ... READ MORE
Delayed second dose and third doses of the Oxford vaccine lead to heightened immune response to COVID-19
A longer delay of up to 45 weeks between the first and second dose of the Oxford-AstraZeneca vaccine leads to enhanced immune response after the second dose, the latest research by the Oxford Vaccine Group has found. They also found that a third dose given more than six months after the second ... READ MORE
Latest data on immune response to COVID-19 reinforces need for vaccination
A new study led by University of Oxford has found that previous infection, whether it was symptomatic or asymptomatic, does not necessarily protect you long term from COVID-19, particularly against new variants of concern. The PITCH Study (Protective Immunity from T cells to COVID-19 in Health ... READ MORE
Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers
Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population. While this is expected to improve with the second dose, this important finding may help influence ... READ MORE
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »